TP-252 for Treatment of Ulcerative Colitis (UC)
TP-252: A pre-clinical asset with clinical proof of concept.
TP-252 is a novel derivative of eicosapentaenoic acid free fatty acid (EPA-FFA), which has been shown in an independent Phase 2 RCT to have efficacy in reducing relapse in ulcerative colitis patients. TP-252 is being developed as adjunct oral therapy to 5-ASAs for the maintenance of remission in ulcerative colitis patients with a history of mild to moderate disease. TP-252 offers safe prospects for extended disease maintenance and delaying the need for escalation to more side-effect prone immuno-suppressants and biologics. Thetis expects to begin clinic studies in 2018.